NEW YORK (GenomeWeb News) – BioTime has raised a further $4 million through the second tranche of a private placement of its common stock and purchase warrants.

The Alameda, Calif.-based firm said that Broadwood Partners and George Karfunkel have each purchased 1.1 million common shares in the firm as well as 1.1 million stock purchase warrants. The warrants are "substantially the same" as BioTime's publicly traded stock purchase warrants, the firm said, and entitles holders to purchase additional common shares at an exercise price of $2 per share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.